Search the site

Spectrum

Here we recognise donors who have made cumulative gifts of $10,000 and above to contribute to children's health research at The Kids Research Institute Australia.

Current donors

We earnestly thank every donor and also acknowledge those who prefer to remain anonymous.

Exclusivity and structure

Learn about the Supply Partner exclusivity and structure at The Kids Research Institute Australia.

Case Studies

Read about some of our current Supply Partners and how we've helped each other grow and develop as united organisations.

Schools

Tailored to spark curiosity and link directly to the Australian curriculum, our schools program engages young minds and bridges the gap between classroom learning and cutting-edge medical research.

Research

A Phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults (Quintet)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

Research

A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

Research

Acute viral bronchiolitis in infants and young children

Anya Deborah Pat Jones Strickland Holt BSc MSc PhD PhD PhD, DSc, FRCPath, FRCPI, FAA Honorary Research Associate Head, Pregnancy and Early Life

Research

Alert Program®

Emma Glenn Martyn Adams Pearson Symons BExSc, MPH BA (Education) PhD Candidate B.A. (Hons) PhD. Acting Research Officer - Playce & PhD student

Research

Australian Strep A Vaccine Initiative (ASAVI)

The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.